Journal: Leukemia
This study evaluated the prognostic impact of myelodysplasia-related (MR) gene mutations in 4,978 intensively treated acute myeloid leukemia (AML) patients, following the European LeukemiaNet 2022 recommendations.
Among the cohort, 34.1% had at least one MR mutation, which was associated with:
- Lower complete remission rates (65.7% vs. 77.7%)
- Worse event-free, relapse-free, and overall survival
Importantly, distinct prognostic patterns were identified within MR mutations:
- Adverse-risk outcomes: ASXL1, RUNX1, SF3B1, and U2AF1 mutations
- Intermediate-risk: SRSF2 and STAG2 mutations
- No significant difference from intermediate or adverse risk: BCOR, EZH2, and ZRSR2 mutations
These findings highlight the heterogeneity among MR mutations and suggest that not all MR mutations confer the same prognostic risk in AML.